On Friday, Rentokil Initial Plc (LSE:RTO) (OTC:RTOKY) stock, a British business services company, saw its stock rating downgraded from "Buy" to "Hold" by Stifel, a financial services firm. The downgrade comes with a revised price target set to £4.20, a decrease from the previous £5.70.
This adjustment follows an unexpected company update on Wednesday that projected the adjusted profit before tax (PBT) for the fiscal year 2024 to be approximately 10% below the consensus, at around £700 million.
The downgrade was prompted by several factors affecting Rentokil's performance, particularly in the North American market. The company experienced weaker organic growth than anticipated in July and August.
As a result, regional organic growth is now expected to be around 1% in the second half of 2024, compared to the previously guided 2.5-3%, which is estimated to impact adjusted operating profit by approximately £20 million.
Additionally, Rentokil expanded its sales and service resources for the peak pest season, leading to over-staffing due to lower-than-expected lead flow. Increased overtime expenses to drive revenues and higher spending on materials and consumables further impacted the operating profit by roughly £50 million. Foreign exchange rates and the easing of hyper-inflation are also expected to create a headwind of around £10 million to the adjusted PBT.
The company's revised forecast for the fiscal year 2024 indicates that North America adjusted operating margins are expected to be 17.2%, compared to Stifel's earlier estimate of 19%. The group's adjusted operating margins are also projected to be lower at 15.5%, against the 16.8% previously estimated by Stifel.
The scale of the profit warning was characterized as a significant surprise by Stifel, citing that higher costs are exacerbating the impact of revenues falling short of expectations. Management has provided additional details on the situation, but has not yet offered guidance for the fiscal year 2025.
In other recent news, Rentokil Initial saw significant attention from various analyst firms. UBS upgraded Rentokil Initial's stock from a Sell to a Neutral rating, setting a new price target at £4.80, up from the previous £3.95. This change was influenced by the involvement of an activist investor and ongoing discussions about the company's value and strategic direction.
Despite the upgrade, UBS acknowledged the risks associated with Rentokil's mid-term targets, particularly as the North American Pest business adapts to a new 'large branch' model.
Similarly, RBC (TSX:RY) Capital maintained its Outperform rating on Rentokil, indicating that despite some volatility, the company is expected to post first-half results in line with forecasts.
Adjustments have been made to Rentokil's earnings per share (EPS) forecasts due to foreign exchange impacts, estimating a slight decrease of 1 to 2%. RBC Capital's analysis suggests potential for increased organic growth in the United States throughout the year.
Citi also maintained a Buy rating on Rentokil's stock, anticipating a robust business update and a year-over-year increase of approximately 2% for the first quarter. This growth is largely attributed to Rentokil's focus on expansion in North America, where demand for pest control services remains strong.
Citi predicts a significant uptick in growth starting from the second quarter, suggesting that the current valuation of Rentokil's shares does not reflect the company's growth potential. These recent developments underline the importance of Rentokil's strategy and execution in the coming months.
InvestingPro Insights
As Rentokil Initial Plc (OTC:RTOKY) navigates through its financial challenges, particularly in the North American market, real-time data from InvestingPro provides a deeper perspective on the company's performance and stock potential. According to InvestingPro, Rentokil boasts an impressive gross profit margin of 82.51% over the last twelve months as of Q2 2024, indicating strong operational efficiency despite recent setbacks. This aligns with the company's ability to maintain profitability, as analysts predict profitability for this year.
However, the stock's recent trajectory suggests caution for investors. The Relative Strength Index (RSI) indicates that Rentokil's stock is currently in oversold territory, and it has experienced a notable decline, trading near its 52-week low. Over the last week alone, the stock has taken a significant hit, with a price total return of -20.24%. On the valuation front, Rentokil is trading at a low P/E ratio of 20.56 relative to near-term earnings growth, which may appeal to value-focused investors.
For those considering a deeper dive into Rentokil's financials and investment potential, InvestingPro offers additional insights and tips. There are currently 6 more InvestingPro Tips available for Rentokil Initial Plc, which can be found at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.